1. Home
  2. ESLA vs COCP Comparison

ESLA vs COCP Comparison

Compare ESLA & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Estrella Immunopharma Inc.

ESLA

Estrella Immunopharma Inc.

HOLD

Current Price

$0.44

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

SELL

Current Price

$1.01

Market Cap

19.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ESLA
COCP
Founded
2021
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.1M
19.2M
IPO Year
2021
2011

Fundamental Metrics

Financial Performance
Metric
ESLA
COCP
Price
$0.44
$1.01
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $8.00
AVG Volume (30 Days)
★ 3.9M
31.9K
Earning Date
11-16-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 54.65
EPS
★ N/A
N/A
Revenue
N/A
★ $12,712,091.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.24
$0.76
52 Week High
$3.01
$2.03

Technical Indicators

Market Signals
Indicator
ESLA
COCP
Relative Strength Index (RSI) 41.78 55.79
Support Level $0.34 $0.91
Resistance Level $0.51 $1.11
Average True Range (ATR) 0.20 0.07
MACD -0.01 0.01
Stochastic Oscillator 19.56 84.21

Price Performance

Historical Comparison
ESLA
COCP

About ESLA Estrella Immunopharma Inc.

Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

Share on Social Networks: